A Novel Assay in Whole Blood Demonstrates Restoration of Mitochondrial Activity in Phagocytes After Successful HSCT in Hyperinflamed X-Linked Chronic Granulomatous Disease

X-linked chronic granulomatous disease is a rare disease caused by mutations in the CYBB gene. While more extensive knowledge is available on genetics, pathogenesis, and possible therapeutic options, mitochondrial activity and its implications on patient monitoring are still not well-characterized....

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical immunology Vol. 42; no. 8; pp. 1742 - 1747
Main Authors Migliavacca, Maddalena, Basso Ricci, Luca, Farinelli, Giada, Calbi, Valeria, Tucci, Francesca, Barzaghi, Federica, Ferrua, Francesca, Cicalese, Maria Pia, Darin, Silvia, Barzaghi, Lina Raffaella, Giglio, Fabio, Peccatori, Jacopo, Fumagalli, Francesca, Nicoletti, Roberto, Giannelli, Stefania, Sartirana, Claudia, Bandiera, Alessandro, Esposito, Maria, Milani, Raffaella, Mazzi, Benedetta, Finocchi, Andrea, Marktel, Sarah, Assanelli, Andrea, Locatelli, Franco, Ciceri, Fabio, Aiuti, Alessandro, Bernardo, Maria Ester
Format Journal Article
LanguageEnglish
Published New York Springer US 01.11.2022
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:X-linked chronic granulomatous disease is a rare disease caused by mutations in the CYBB gene. While more extensive knowledge is available on genetics, pathogenesis, and possible therapeutic options, mitochondrial activity and its implications on patient monitoring are still not well-characterized. We have developed a novel protocol to study mitochondrial activity on whole blood of XCGD patients before and after transplantation, as well as on XCGD carriers. Here we present results of these analyses and of the restoration of mitochondrial activity in hyperinflamed X-linked Chronic Granulomatous Disease after hematopoietic stem cell transplantation. Moreover, we show a strong direct correlation between mitochondrial activity, chimerism, and DHR monitored before and after transplantation and in XCGD carriers. In conclusion, based on these findings, we suggest testing this new ready-to-use marker to better characterize patients before and after treatment and to investigate disease expression in carriers.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0271-9142
1573-2592
1573-2592
DOI:10.1007/s10875-022-01338-x